INTRODUCTION
Multiple myeloma (MM) is characterized by abnormal proliferation of malignant plasma cells (PCs) within the bone marrow (BM), which leads to paraprotein release in the serum, osteolytic bone disease, anemia and renal failure [ 1 ]. Despite in the recent years important achievements in the understanding of MM pathogenesis have been obtained [ 2 ] and novel research platforms [ 3 - 5 ] and new therapeutics [ 6 , 7 ] have been made available, MM invariably progresses to a lethal stage and is still an incurable malignancy. Disease progression is sustained by a supportive network which is based on complex cross-talks and involves a variety of cells of the human bone marrow milieu (huBMM), including endothelial, inflammatory and stromal cells. In this context, the BM angiogenesis plays a critical role in the MM pathogenesis and progression [ 8 ] and MM has been the first hematological disease in which the prognostic relevance of angiogenesis has been demonstrated [ 9 , 10 ]. Interestingly, several studies indicate that monoclonal gammopathy of undetermined significance (MGUS) and non-active MM (smoldering MM) represent the avascular phase of PC malignancies, while active intramedullary MM is the vascular phase of the disease. In line with these data, increased BM micro-vessel density (BM-MVD) was observed in patients with active MM and was correlated to disease progression, adverse outcome and resistance to chemotherapy [ 11 ]. MM cells promote the angiogenic switch through the direct expression of angiogenic molecules or their induction in the BM stromal cells (BMSCs) within the huBMM [ 12 ]. In fact, BMSCs may cooperate with malignant PCs to produce pro-angiogenic factors, which finally induce full angiogenic events. In this contest, a critical role in the regulation of the angiogenic switch is played by the hypoxic huBMM: in fact, it is now becoming clear that MM cells are chronically exposed to low oxygen levels and abnormally activate hypoxia-inducible factors (HIFs) [ 11 , 13 ]. The aberrant HIFs activation in turn increases the BM angiogenesis via up-regulation of VEGF-A, IL8 and CXCL12 [ 14 ]. In addition, the hypoxia supports MM cells survival, invasion, also contributing to disease progression and development of drug-resistance [ 15 , 16 ].
Notably, HIF-1α suppression in myeloma cells blocks tumoral growth in vivo and interferes negatively with angiogenesis and bone destruction [ 17 ].
Recent findings have highlighted a relevant role for microRNAs (miRNAs) in the regulation of angiogenic events [ 18 , 19 ]. miRNAs are short non-coding RNA molecules able to regulate gene expression, affecting the stability and/or translation of target mRNAs [ 20 ]. In MM, specific miRNA signatures have been associated to different steps of MM development from normal PCs via MGUS to clinically overt MM [ 21 , 22 ]. Therefore a strong relationship between deregulated expression of miRNAs and the tumor phenotype has been demonstrated [ 21 - 26 ] and miRNA deregulation has been associated to the typical chromosomal aberrations [ 21 , 22 , 27 , 28 ]. More recently, miRNAs beyond their key role in MM pathogenesis, are emerging as potential tools for the targeting the miRNA network as a novel therapeutic strategy providing a novel rationale and a new venue of investigation in this disease [ 29 - 37 ]. There is now strong evidence that hypoxia controls miRNAs expression in cancer [ 38 - 40 ]; in turn, hypoxia-regulated miRNAs interfere with a large variety of processes such as angiogenesis, apoptosis, proliferation and migration [ 39 ]. Among miRNAs deregulated in MM, miR-199a-5p is of relevant interest because directly targets HIF1-α, a prominent transcription factor which regulates angiogenesis, predominantly via induction of VEGF transcription [ 41 - 43 ]. Furthermore, it has been demonstrated that hypoxia induces down-regulation of miR-199a-5p, probably through activation of the AKT pathway [ 44 , 45 ].
On these premises, we investigated the functional role of miR-199-5p in MM. We first evaluated its expression in a panel of MM cell lines and then we studied the biological effect induced in vitro by enforced expression of synthetic miR-199a-5p mimics in both normoxic and hypoxic conditions. Moreover, we studied the anti-tumor potential of in vivo delivered of miR-199a-5p against human MM xenografts in mice. We believe that our results disclose a relevant role of miR-199a-5p in MM-angiogenesis and provide the rationale for the design of innovative miRNA-based therapeutic approach in this disease.
RESULTS
miR-199a-5p expression in human MM cell lines and hypoxic-response of MM cells
We first evaluated the miR-199a expression profile in a set of MM cell lines (OPM2, U266, KMS11, MM1S, RPMI 8266, KMS34, INA6, KMS-12M, NCI-H929, SKMM1) as compared to normal BM-derived CD138 + PCs from healthy donors.
Among cell lines analyzed by qRT-PCR, we found that miR-199a-5p is significantly down-regulated in 4 (OPM2, U266, KMS11, MM1S) out of 10 lines as compared to normal PCs (Fig. 1A ).
To study the response of MM cells to hypoxia, we reproduced an hypoxic condition by the use of cobalt chloride or by culturing cells for at least 24 hours in a 1% O 2 atmosphere. By western blotting analysis of nuclear-enriched extracts from CoCl 2 -stimulated MM cells, we found that hypoxic conditions triggered the increase of HIF-1α levels in MM cells (Fig. 1B ). Similar results were obtained when MM cells were cultured in a hypoxia chamber (data not shown).
In parallel, we analyzed the expression of miR-199a-5p in response to hypoxia in MM cells. To this end, we used MM cell lines with different basal levels of miR-199a-5p in standard conditions. We observed a significant decrease of miR-199a-5p expression in hypoxic MM cells as compared to normoxic counterpart (Fig. 1C ). Notably, miR-199a-5p expression was further decreased when MM cells where co-cultured with hypoxic BMSCs (Fig. 1D ). These results indicate that hypoxia in MM cells down-regulate miR-199a-5p and this effect is further strengthened by an hypoxic huBMM.
miR-199a-5p targets and suppresses HIF-1α expression into hypoxic MM cells
To assess whether miR-199a-5p directly affects the expression of HIF-1-α in MM cells, we evaluated the effect induced by enforced expression of synthetic miR-199a-5p mimics on HIF-1-α protein levels in cells exposed to hypoxic culture conditions. By qRT–PCR, we first measured the transfection efficiency of miR-199a-5p 24h after treatment ( Supplemental Figure 1A ). Notably, we observed that enforced expression of miR199a-5p into hypoxic MM cells strongly suppressed nuclear HIF-1α protein expression (Fig. 2A ).
To validate this interaction in MM cells, OPM2 were co-transfected with synthetic miR- 199a-5p or scrambled oligonucleotides (NC), together with an expression vector carrying the 3'UTR of HIF-1α mRNA cloned downstream to the luciferase reporter gene. Figure 2B clearly shows a significantly lower luciferase activity in OPM2 cells transfected with miR-199a-5p mimics as compared to the control.
Moreover, we investigated the effect induced on the mammalian class-III protein deacetylase of the sirtuin family (Sirt1), a putative target of miR-199a-5p which plays an important role in stabilizing HIF-1α. As shown in Fig. 2C , miR-199a-5p indeed reduced Sirt1 protein expression.
miR-199a-5p inhibits the hypoxic induction of pro-angiogenic factors and reduces endothelial cells migration
qRT-PCR basal analysis of hypoxic MM cells revealed that VEGF-A and IL-8 mRNA expression were about 8 and 10-fold higher as compared to normoxic cells ( Supplemental Fig. 2A ). Moreover, we found that mRNA basic-fibroblast growth factor-2 (bFGF) expression was approximately 5-fold higher in hypoxic as compared to normoxic cells ( Supplemental Fig. 2A ). On the basis of these findings, we attempted to restore the miR-199a-5p expression in MM cells in order to evaluate its activity on the expression of pro-angiogenic factors. We indeed found that enforced expression of miR199a-5p mimics significantly reduced VEGF-A, IL-8 and bFGF mRNA, both in normoxic as well as in hypoxic cells (Fig. 3A ). Taking in account that secretion is increased in hypoxic MM cells, we investigated whether enforced expression of miR-199a-5p in hypoxic MM cells was able to reduce VEGF-A protein secretion. Figure 3 B shows that miR-199a-5p transfection in myeloma cells significantly decreased VEGF-a protein secretion
To investigate the role of miR-199a-5p in endothelial cells migration, we performed a chemotaxis assay. We observed that miR-199a-5p mimics produced a relevant decrease in the number of endothelial migrating cells in normoxic condition (Fig. 3C ). Furthermore, addition of normoxic conditioned medium from MM cells over-expressing miR-199a-5p to the endothelial monolayer reduced the expression of cell-cell adhesion molecules such as VCAM-1 and ICAM-1 (Fig. 3D ). Accordingly, the expression of VEGF-A and IL-8 mRNA produced by endothelial cells, were also significantly decreased (Fig. 3D ).
Taken together, these results indicate that miR-199a-5p directly inhibits the synthesis of angiogenic factors by MM cells and interferes with the MM/endothelial cell loop which promotes the basic events in the angiogenic response.
miR-199a-5p regulates DDR1 expression and decreases chemotaxis of MM cells
The discoidin domain receptor-1 (DDR1) is a predicted target of miR-199a-5p [ 41 ]. Here we investigated if its expression was regulated by miR-199a-5p in MM cells. We analyzed DDR1 expression in both normoxic and hypoxic MM cells transfected with miR-199a-5p. Western blot analysis demonstrated a strong reduction of DDR1 expression in hypoxic MM cells (Fig. 4A ). qRT-PCR basal analysis of hypoxic MM cells revealed that MMP2 mRNA expression was about 5-fold higher as compared to normoxic cells ( Supplemental Fig. 2B ). Conversely, we found a decrease in metalloproteinase MMP2 also, at mRNA and protein level, both in normoxic and hypoxic MM cells transfected with miR-199a-5p, although these latter effects were mainly detectable in hypoxic conditions (Fig. 4A-B ).
To assess the effect of miR-199a-5p expression on the migration of MM cells, we performed a chemotaxis assay on hypoxic and normoxic MM cells. Figure 4C shows that miR-199a-5p transfection reduces the percentage of MM migrating cells both in normoxic and in hypoxic conditions.
miR-199a-5p induces adhesion to hypoxic BMSCs
In order to investigate the role of miR-199a-5p in the adhesion of MM cells to BMSCs, we first found that hypoxia reduces the adhesion of MM cells to a BMSCs monolayer ( Supplemental Fig. 3A ). Conversely, we showed that the enforced expression of miR-199a-5p reconstituted the adhesion capacity of hypoxic MM cells to a monolayer of hypoxic BMSCs (Fig. 5A ). Moreover, hypoxic MM cells transfected with miR-199a-5p expressed higher levels of E-cadherin and lower levels of Snail mRNA (Fig. 5B-C ). Supplemental figure 3B shows that the expression of CXCR4 mRNA was increased in hypoxic MM cells, while mR-199a-5p transfection decreased CXCR4 mRNA levels (Fig. 5D ). In addition, BMSCs exposed to conditioned medium of miR-199a-5p-transfected MM cells showed impaired expression of IL6 and IL8. Taken together these findings demonstrate that miR199a-5p is able to reverse the invasive phenotype induced by hypoxic BM microenvironment.
miR-199a-5p decreases cell proliferation and increases apoptosis in hypoxic conditions
To evaluate the effects induced by enforced expression of miR-199a-5p on MM cell growth, we analyzed cell proliferation, cell cycle and apoptosis. As shown in Figure 6 A, enforced expression of miR199a-5p decreased cell growth in all MM cell lines analyzed; in particular, cell growth inhibition was more evident 72 hours after transfection. Cell-cycle analysis showed that miR-199a-5p induced only a slight increase in G1 and a decrease in S-G2 phases under hypoxic conditions (Data not shown). Notably, we found up-regulation of the cell-cycle inhibitors p21 Cip-1 and p27 kip-1 , even if this effect occurred only in hypoxic MM cells (Fig. 6B ). Furthermore, flow cytometry demonstrated that miR-199a-5p induced apoptosis only in hypoxic MM cells (Fig. 6C ). Western blot analysis revealed that miR-199a-5p-induced apoptosis was associated to activation of pro-apoptotic proteins caspase 3/7 and cleaved poly ADP-ribose polymerase (PARP), as well as reduction of the anti-apoptotic BCL-2 protein (Fig. 6D ). All together these findings provide evidence that enforced expression of miR-199a-5p exert antitumor activity in conditions that recapitulate the MM hypoxic huBMM.
AKT pathway regulates miR-199a-5p activity in hypoxia
To investigate the molecular mechanism of miR-199a-5p down-regulation in hypoxic MM cells, we over-expressed AKT1 in MM cells and we evaluated for the miR-199a-5p expression. As shown in Fig. 7A , over-expression of AKT1 induced down-regulation of miR-199a-5p. Furthermore, when MM cells were treated with the PI3-K/AKT inhibitor LY294002, we observed restoration of miR-199a-5p expression (Fig. 7B ). In addition, we silenced transiently AKT1 in MM cells and we found an increase of miR-199a-5p expression (Fig. 7C ). Interestingly, after miR-199a-5p transfection in MM cells, we found a reduction of total and phosphorylated AKT1 protein levels (Fig. 7D ). These data indicate the occurrence of a negative feedback loop between miR-199a-5p and AKT pathway where miR-199a-5p negatively regulates AKT expression, while activation and functional AKT represses miR-199a-5p expression ( Supplemental Fig. 4A ).
Another mechanism that control the expression of miR-199a is the methylation status of its promoters on both Chr1 and Chr19 [ 42 , 46 ]. To investigate possible epigenetic mechanisms involved in the down-modulated expression of miR-199a-5p, we treated MM cells with the DNA demethylating agent 5-aza-dC [ 47 ]. This experiment was performed in three different cell lines expressing different levels of miR199a-5p and we found that miR-199a-5p expression was increased only in the two cell lines where its levels are low ( Supplemental Figure 5A ). In contrast, no differences were observed in cells where miR199a-5p is not down-regulated.
In order to clarify if down-regulation of miR-199a-5p in MM cell lines specifically depend by hypermethylation of its two promoter regions in chromosome 19 (1a) and in chromosome 1 (2a), respectively, the methylation levels of CpG sites located within these regions were evaluated by Sequenom MassARRAY EpiTYPER. To this aim, OPM2, U266 and NCI-H929 MM cells were treated with 1μM 5-azacytidine or with vehicle (RPMI medium) [ 36 ].
We observed that the methylation status of the promoter regions remained basically unchanged, ( Supplemental Fig. 5B ) despite that the azacytidine treatment increased miR-199a-5p levels in OPM2 and U266 MM cells (data not shown).
In order to further verify if the demethylation of miR-199a promoters was dose-dependent, we treated U266 cell line with either 5μM 5-azacytidine or with trichostatin A, a histone deacetylase inhibitor with demethylating activity. Again we did not observe demethylation of miR-199a-5p ( Supplemental Fig. 5C ) of both promoter regions.
These results suggest that the increase of miR-199a-5p expression following treatment with 5-AZA does not involve the de-methylation of mir199a-5p promoters thus suggesting an alternative as yet unidentified epigenetic mechanism.
In vivo anti-tumor activity of formulated miR-199a-5p against MM xenografts
We next investigated the effect of miR-199a-5p treatment on MM xenograft growth in NOD-SCID mice. miR-199a-5p or miR-NC were administered with NLE particles, a formulation specifically designed for the delivery of oligonucleotides in vivo . A highly significant (P<0,05) inhibition of tumor growth was detected following 6 injections (3 days apart) of miR-199a-5p formulated in NLE particles in NCI-H929 xenografts (Fig. 8A ). Furthermore, we observed a prolongation of survival ( P=0.02 ) of mice treated with miR-199a-5p mimics compared to control groups (median survival was 29 days versus 20 days in the control group) (Fig. 8B ). We therefore conclude that miR-199a-5p by intratumoral delivery is highly effective against MM xenografts and significantly prolongs host survival.
DISCUSSION
MM growth and progression is characterized by relevant angiogenic events that occur within the huBBM chronically exposed to low oxygen levels [ 11 , 48 , 49 ]. The BM hypoxia triggers the expression of a variety of genes essential for adaptation, cell invasion, dissemination and drug-resistance of MM cells [ 50 ]. Indeed, the hypoxia inducible-factor 1-α (HIF-1α), the master regulator of cellular response to hypoxia, is known to be abnormally activated in the BM of MM patients. Aberrant HIF1-α activation in MM cells contributes to the pathogenesis of the disease increasing angiogenesis via up-regulation of IL-8 and VEGF-A [ 8 ]. In this scenario, a variety of miRNAs have been found to play a relevant role as regulators of huBMM angiogenic events [ 51 - 53 ].
Here, we focused on the role of miR-199a-5p in both normoxic and hypoxic MM cells, because HIF-1α is predicted to be a potential target of miR-199a-5p [ 54 ]. It has been reported that miR-199a-5p is down-regulated in hypoxic conditions and specifically targets the 3'-UTR region of HIF-1α [ 55 ]. Importantly, miR-199a-5p is down-regulated in a variety of malignancies including MM where its deregulation seems to be correlated with chromosomal aberrations [ 54 , 56 ]. Consistent with these observations, we found a deregulated expression of miR-199a-5p in myeloma cell lines.
To investigate the potential role of miR-199a-5p in a pathological hypoxic context, we selected MM cell lines with lower levels of miR-199a-5p as compared to normal CD138 + cells. Using these cells, we found a reduction of miR-199a-5p expression in both cells exposed to hypoxic conditions and co-cultured with hypoxic BMSCs. Importantly, we showed that enforced expression of miR-199a-5p significantly down-regulated the expression of HIF-1α in hypoxia-induced MM cells. In addition, we validated HIF-1α as a direct target of miR-199a-5p in myeloma cells. Accordingly, we found a strong reduction of Sirt1 expression, another miR-199a-5p predicted target required for HIF-1α accumulation [ 55 , 57 ]. Interestingly, among the pro-angiogenic genes directly regulated by HIF-1α in MM cells, VEGF-A and IL-8 were strongly reduced after miR-199a-5p transfection, mainly in hypoxic conditions [ 11 , 58 , 59 ]. Consistent with these results, conditioned medium by miR-199a-5p-transfected hypoxic cells impaired IL-6 secretion by BMSCs. Consistent with the previously reported findings, the over-expression of miR-199a-5p in MM cells caused a decrease of bFGF expression, an important pro-angiogenic factor involved also in endothelial cell migration [ 60 - 63 ]. In fact, miR-199a-5p transfected MM cells reduced the migration of endothelial cells. Notably, this effect was associated to a significantly decreased expression of cell-cell adhesion molecules in endothelial cells such as VCAM-1 and ICAM-1. All together, these results suggest that restoration of miR-199a-5p has an important effect on myeloma-induced angiogenesis, acting on the production of pro-angiogenic factors by cells of the hypoxic microenvironment.
The discoidin domain receptor-1 (DDR1) is a collagen tyrosine kinase over-expressed in several human cancers [ 64 ]. Several studies suggested a potential role of DDR1 in tumor cell migration and invasion, usually mediated by extracellular matrix degradation; in addition, also DDR1 mRNA is predicted to be a potential target of miR-199a-5p [ 41 ]. In our study we found that repression of DDR1 protein upon enforced expression of miR-199a-5p occurred together with a reduced cellular migration and reduced expression of the matrix metalloproteinase MMP2. In parallel, miR-199a-5p reduces the expression of CXCR4 in hypoxic conditions.
A recent report demonstrated that hypoxia reduces adhesion of MM cells to the BM stroma thus promoting dissemination [ 65 ]. In detail, the authors showed clearly that the mechanism by which hypoxia leads to de-adhesion of MM cells to the BM stroma is mediated by E-cadherin, one of the most important molecules in cell-cell adhesion [ 65 ]. In an hypoxic context, HIF-1α recognizes Snail gene promoter leading to a decrease of E-cadherin expression thus resulting in an impairment of cell-cell adhesion and promotion of motility, invasion and metastasis [ 66 - 68 ].
In our study, we first validated HIF-1α as direct target of miR-199a-5p and then we evaluated if miR-199a-5p restoration in MM cells could have a role in the mechanism described above.
Hypoxic MM cells were transfected with miR-199a-5p and, once HIF-1α was blocked, we observed the inhibition of Snail expression and higher levels of E-cadherin.
We provide the first evidence, at our knowledge, that enforced expression of miR-199a-5p increases the percentage of hypoxic MM cells adherent to a monolayer of hypoxic BMSCs.
Taken together, these data suggest that i ) miR199a-5p has a role in regulating tumor dissemination induced by hypoxia, and that ii ) miR-199a-5p modulates tumor cell migration, at least in part by targeting DDR1.
Furthermore, we demonstrated that the enforced expression of miR-199a-5p triggers anti-proliferative and pro-apoptotic effects in hypoxic MM cells. Importantly, all our observations translated in a significant in vivo activity of formulated synthetic miR-199a-5b delivery which add potential clinical significance to our study. Together with the significant inhibition of tumor growth, we indeed achieve a clear advantage in terms of mice survival. This result is of great interest since conventional MM xenografts are based on aggressive established cell lines which produce quickly growing tumors poorly vascularized providing therefore an in vivo suitable informative system predictive of therapeutic response.
On the basis of this finding demonstrating a role for miR-199a-5p in MM angiogenic response and control of cell growth and survival, we investigated the molecular mechanism responsible of the miR-199a-5p downregulation in MM. It is well known that exposure to hypoxia elicits an adaptive response that also involves activation of the AKT pathway. It is well known that AKT enhances survival and anti-apoptotic gene expression acting also through miRNA-dependent mechanisms [ 69 ]. In particular, AKT induces downregulation of miR-199a-5p, which is required for de-repression of Hif-1α [ 45 , 55 ]. Here, we demonstrated that functional AKT1 overexpression is sufficient in repressing miR-199a-5p expression while AKT1 depletion results in an increase of miR-199a-5p. Notably, miR-199a-5p induced also a reduction of total and phosphorylated AKT proteins expression. Although the precise molecular mechanisms underlying miR-199a-5p/Akt in MM needs to be fully elucidated, these results provide insights on miR-199a-5p-Akt pathway cross-talk in MM indicating the occurrence of a regulatory negative loop where miR-199a-5p downregulates functional AKT which, in turn, represses miR-199-5p [ 70 ]. Recent findings indicate that miR-199a expression is finely regulated also by promoter methylation on both Chr1 and Chr19, where its gene is located. Indeed, studies in several cancer cell lines showed that both promoter regions on Chr1 and Chr19 were hypermethylated [ 46 , 71 , 72 ]. Our findings indicate that treatment with demethylating agent can induce a restoration of miR-199a-5p expression in MM cells even if we can rule out, at least in our experimental conditions, a direct correlation with the methylation status of its promoter.
Treatments targeting the MM hypoxic niche are currently considered novel and promising therapeutics strategies.
In summary, our results revealed that hypoxia down-regulates the expression of miR-199a-5p in MM via activation of AKT in order to allow the up regulation of HIF-1α and pro-angiogenic genes. Our investigation provides evidence on miR-199a-5p involvement in cell proliferation, migration and apoptosis and suggests a critical role for miR-199a-5p in the hypoxic tumor microenvironment. Taken together, these data support the development of miR-199a-5p mimics as a new potential therapeutic agents in the treatment of MM. The important interaction with AKT pathway opens new opportunities for combinatory therapeutical approaches which may result in a selective and highly efficient targeting of pathways crucially involved in the control of MM cell growth and survival in the huBMM.
MATERIALS AND METHODS
Cell Lines, Primary Cells and Drugs
MM cell lines were purchased from ATTC and grown in RPMI-1640 (Gibco, Life Technologies, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (Lonza Group, Basel, Switzerland). HUVEC were obtained from Lonza (Clonetics, Verviers, Belgium) and grown in endothelial growth medium (EGM) according to supplier's information.
Stromal HS-5 cells were purchased from ATCC and cultured in Dulbecco's modified Eagle's medium, supplemented with 10% fetal bovine serum.
To induce hypoxia conditions, cells were placed in a modular incubator chamber (STEMCELL Technologies Inc., Vancouver, BC, Canada) and flushed for 5 minutes with a gas mixture of 5% CO 2 -95% N2; the final medium pO2 value was 2%. The chamber was then sealed and placed at 37°C in conventional cell incubator.
Alternately, cells were treated for 4 hours with 100µM/L of the hypoxia-mimicking CoCl 2 (Sigma-Aldrich) which increased baseline levels of HIF-1α.
5-Azacytidine and PI3K inhibitor LY294002 were purchased from Sigma Aldrich and Cell Signaling (Danvers, MA, USA), respectively.
In vitro transfection of MM cells with synthetic mir-199a-5p
Synthetic pre-miRNAs were purchased from Ambion (miRNA mimic MC10893, Applied Biosystems). 1×10 6 cells were electroporated with scrambled (miR-NC) or synthetic pre-miR-199a-5p (miR-199a-5p) at a final concentration of 100nM, using Neon Transfection System (Invitrogen), with 1050 V, 30ms, 1 pulse. Cell transfection efficiency was evaluated by flow cytometric analysis of FAM™ dye-labeled synthetic miRNA inhibitor (Invitrogen) transfection.
Quantitative real-time amplification of miRNAs and mRNAs
Total cellular RNA was extracted using TRIzol Reagent (Invitrogen, Life Technologies, Carlsbad, CA, USA) according to the manufacturer's protocol. qRT–PCR was used to confirm the expression levels of mRNAs and miRNAs.
The single-tube TaqMan miRNA (Assay ID 000498, Applied Biosystems, Life Technologies) was used to detect and quantify mature miR-199a-5p according to the manufacturer's instructions, by the use of iQ5 multicolor detection system (Bio-Rad, Berkeley, CA, USA). miR-199a-5p expression was normalized on RNU44 (Applied Biosystems, Assay Id 001094).
For mRNA detection, oligo-dT-primed cDNA was obtained using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems) and then used as template to quantify VEGF-A(hs00900054_m1), IL-8 (hs00174103_m1), IL-6(hs00985639_m1), FGFb (hs00266645_m1), MMP-2(hs01548727_m1), CXCR4(hs00237052_m1), SNAIL (hs00195591_m1), VCAM1(hs01003370_m1), ICAM1(hs00277001_m1), AKT1 (hs00920512_m1) levels by TaqMan assay (Applied Biosystems); normalization was performed with B-actin. Comparative real time polymerase chain reaction (RT–PCR) was performed in triplicate, including no-template controls. Relative expression was calculated using the comparative cross threshold (Ct) method.
Western blotting and antibodies
SDS-PAGE and Western Blotting (WB) were performed according to standard protocols [ 73 ]. Briefly, cells were lysed in lysis buffer containing 15mM Tris/HCl pH7.5, 120mM NaCl, 25mM KCl, 1mM EDTA, 0.5% Triton X100, Halt Protease Inhibitor Single-Use cocktail (100X, Thermo Scientific). Whole lysate (50µg per lane) were separated using 4-12% Novex Bis-Tris SDS-acrylamide gels (Invitrogen), electro-transferred on Nitrocellulose membranes (Bio-Rad), and immunoblotted with the appropriate antibodies. The antibodies against the following proteins were used for the procedure: Histone H3 (D1H2), HIF-1-α (#3716), E-cadherin (clone 24E10), Phospho-Akt (Ser473), Akt (pan) (C67E7), Caspase-7 (#9492), Caspase-3 (#9662), Cleaved PARP (Asp214; D64E10) were obtained from Cell Signaling (Beverly, MA). SIRT1 from Serotec and VEGF-A (MAB293) from R&D systems; α-Tubulin (C-20), MMP2 (2C1), DDR1 (C-20), p21 Cip1 (sc-397), p27 Kip1 (sc-528), Bcl-2 (sc-7382), and all secondary antibodies were obtained from Santa Cruz Biotechnology (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA). Chemiluminescence was detected using Pierce ECL Western Blotting Substrate (cat. 32109, Pierce, USA).
Nuclear fraction-enrichment
Cells were lysed in cytoplasm lysis buffer A (10mM HEPES pH 7.9, 10mM KCl, 0.2mM EDTA and 1mM DTT), containing protease inhibitors, 0.5mM phenylmethylsulfonylfluoride (PMSF) and 0.6% Nonidet P-40 (Sigma Chemical Co., St. Louis, MO, USA). Lysates were centrifuged at 10,000 r.p.m. for 10 min at 4°C, and the supernatants (cytoplasmic fractions) were split into aliquots and rapidly frozen. The nuclear pellet was washed in buffer A without Nonidet P-40 and finally resuspended in nuclear lysis buffer B (20mM HEPES pH 7.9, 0.4M NaCl, 2mM EDTA, 1mM DTT), containing protease inhibitors and 1mM PMSF (Sigma Chemical Co.). Samples were incubated on ice for 30 min and centrifuged at 13 000 r.p.m. for 10 min at 4 °C; the supernatants (nuclear fractions) were split into aliquots and rapidly frozen. The remaining pellets, containing DNA as well as proteins tightly associated with DNA, were washed in reticulocyte buffered buffer (RSB: 10mM NaCl, 10mM Tris-HCl pH 7.5 and 1.5mM MgCl2) and finally resuspended in RSB and HCl 0.4N to obtain HCl-soluble proteins [ 74 , 75 ]. The samples were incubated at least 1 h at 4 °C and centrifuged at 10 000 r.p.m. for 20 min at 4 °C. The acid-soluble proteins were recovered from the supernatants by precipitation with 10 volumes of acetone at -20°C and centrifugation at 10,000 r.p.m. for 20 min at 4 °C. HCl-soluble proteins were finally resuspended in distilled water, split into aliquots and frozen.
Cell proliferation
For cell proliferation analysis, MM cells were plated in 6 well plates, electroporated with miR-199a-5p or miR-NC and then harvested, plated at 1,5-2,0×10 5 /ml, and counted at 24 hours intervals using a Trypan Blue-exclusion assay.
Annexin v apoptosis assays
Annexin V apoptosis assays were performed using Annexin V-FITC kit (Biolegend, San Diego, CA, USA) according to manufacturer's protocol. The stained cells were immediately analyzed on a FACScalibur flow cytometer (Becton Dickinson). The data were presented as the percentage of apoptotic cells.
Chemotaxis assay
Chemotaxis was determined using 8-u-pore filters for the Transwell migration assay (BD Biosciences), according to the manufacturer's instructions.
Briefly, OPM2 cells (1×10 5 /well) transfected with either scrambled (miR-NC) or synthetic pre-miR-199a-5p (miR-199a-5p) were washed and resuspended in RPMI 1640 medium supplemented with 1% FBS. Then cells were placed in the upper migration chambers, whereas the lower chamber contained RPMI 1640 medium supplemented with 10% FBS. After 5 hours of incubation at 37°C-5%CO 2 , cells migrated to the lower chambers were determined by a Trypan-Blue exclusion assay. Huvec (7×10 3 cells/well) were resuspended in serum free RPMI 1640 medium supplemented with 0.1% BSA in transwell chemotaxis (BD Biosciences) above 8 um pore filters and exposed to conditioned medium from multiple myeloma cells transfected with either scrambled (miR-NC) or synthetic pre-miR-199a-5p (miR-199a-5p).
Filters were removed after 6 hours, fixed in methanol and stained with Diff-Quick (Medion Diagnostics GmbH). Two independent experiments were carried out in triplicate; cells from five different fields were counted for each condition.
Adhesion assay
HS-5 stromal cells were grown to confluence in 12-well plates and fixed with glutaraldehyde 0.0125% (Agar Scientific LTD). After fixation, cells were treated with 10 mM ethanolamine to block aldehydic groups and washed several times before plating MM cells.OPM2 cells (0.5×10 6 cells/well) transfected with either scrambled (miR-NC) or synthetic pre-miR-199a-5p (miR-199a-5p) were added to each well and incubated for 4 hours at 37°C-5%CO 2 . Non adherent cells were washed and adhesion was detected by hematoxylin/eosin staining. Each test group was assayed in triplicate; five fields were counted for each condition.For cells cultured under hypoxic conditions, all procedures were performed in the hypoxic chamber (STEMCELL Technologies Inc.).
Luciferase reporter experiments
The 3'UTR of HIF-1α were cloned in pEZX-MT01 vector and purchased from Genecopoeia. MM cells were electroporated as above described using 10µg of the firefly luciferase reporter; for each plate, 100 nM of the synthetic miR-199a-5p or miR-NC were used. Firefly and Renilla luciferase activities were measured consecutively using the dual-luciferase assay kit (Promega Corporation, Madison, WI, USA) 24 hours after transfection.
Data are expressed as luminescence from firefly luciferase divided by luminescence from renilla luciferase.
Animals and in vivo models of human MM
Male CB-17 non-obese diabetic/severe combined immunodeficient (NOD.SCID) mice (6- to 8-weeks old; Harlan Laboratories, Inc., Indianapolis, IN, US) were housed and monitored in our Animal Research Facility. All experimental procedures and protocols had been approved by the Institutional Ethical Committee and conducted according to protocols approved by the National Directorate of Veterinary Services (Italy). In accordance with institutional guidelines, mice were sacrificed when their tumors reached 2 cm in diameter or in the event of paralysis or major compromise in their quality of life, to prevent unnecessary suffering. To obtain xenograft model of human MM, 5×10 6 NCI-H929 cells in 100 µL RPMI-1640 medium were subcutaneously injected into the interscapular area of NOD-SCID mice. Treatments were initiated after the detection of palpable tumors, (approximately 30 mm 3 ), about 10 days following the injection of MM cells. The tumor sizes were measured as previously described [ 30 ] Mice were randomized into 2 groups and treated with synthetic miR-199a-5p mimics (Life Technologies) or scramble control (miR-NC). Each dose contained 20 µg synthetic oligo, which equals 1mg/kg per mouse with an average weight of 20 g. Administration of miRNAs mimics was performed by the use of the neutral lipid emulsion (NLE) (MaxSuppressor in vivo RNA Lancer II, BIOO Scientific, Austin, TX) as previously described [ 76 ]. Treatments were performed intratumorally (i.t.) every three days for a total of six injections.
Elisa
VEGF-A levels secreted by MM cells were quantified by VEGF–enzyme-linked immunosorbent assays (Quantikine ELISA) (R&D Systems, Minneapolis, MN), according to the manufacturer's recommendations.
Briefly, OPM2 cells (1×10 6 cells/well) transfected with either scrambled (miR-NC) or synthetic pre-miR-199a-5p (miR-199a-5p) were added to each well in RPMI supplemented with 1% FBS and cultured in both normoxic and hypoxic conditions. Supernatants were harvested after 48 hours and analyzed.
Statistical analysis
The data were expressed as means±s.d. Differences were assessed by two tailed Student's t-test using the Excel software. P value < 0.05 was considered to be statistically significant.
SUPPLEMENTARY FIGURES AND TABLE
The authors declare no conflict of interest.
This work was supported by funds of Italian Association for Cancer Research (AIRC), PI: PT. ‘Special Program Molecular Clinical Oncology—5 per mille’ n. 9980, 2010/15.
REFERENCES
1 Palumbo A Anderson K Multiple myeloma N Engl J Med 2011 364 11 1046 1060 21410373 10.1056/NEJMra1011442
2 Munshi NC Anderson KC New strategies in the treatment of multiple myeloma Clin Cancer Res 2013 19 13 3337 3344 23515406 10.1158/1078-0432.CCR-12-1881 PMC4112820
3 Calimeri T Battista E Conforti F Neri P Di Martino MT Rossi M Foresta U Piro E Ferrara F Amorosi A Bahlis N Anderson KC Munshi N Tagliaferri P Causa F Tassone P A unique three-dimensional SCID-polymeric scaffold (SCID-synth-hu) model for in vivo expansion of human primary multiple myeloma cells Leukemia 25 4 707 711 21233838 10.1038/leu.2010.300 PMC3089835
4 Tassone P Neri P Carrasco DR Burger R Goldmacher VS Fram R Munshi V Shammas MA Catley L Jacob GS Venuta S Anderson KC Munshi NC A clinically relevant SCID-hu in vivo model of human multiple myeloma Blood 2005 106 2 713 716 15817674 10.1182/blood-2005-01-0373 PMC1895174
5 Tassone P Neri P Burger R Di Martino MT Leone E Amodio N Caraglia M Tagliaferri P Mouse models as a translational platform for the development of new therapeutic agents in multiple myeloma Curr Cancer Drug Targets 2012 12 7 814 822 22671927 10.2174/156800912802429292 PMC3587184
6 Rossi M Di Martino MT Morelli E Leotta M Rizzo A Grimaldi A Misso G Tassone P Caraglia M Molecular targets for the treatment of multiple myeloma Curr Cancer Drug Targets 2012 12 7 757 767 22671925 10.2174/156800912802429300
7 Misso G Zappavigna S Castellano M De Rosa G Di Martino MT Tagliaferri P Tassone P Caraglia M Emerging pathways as individualized therapeutic target of multiple myeloma Expert opinion on biological therapy 2013 13 Suppl 1 S95 109 23738692 10.1517/14712598.2013.807338
8 Giuliani N Storti P Bolzoni M Palma BD Bonomini S Angiogenesis and multiple myeloma Cancer Microenviron 4 3 325 337 21735169 10.1007/s12307-011-0072-9 PMC3234322
9 Fan F Schimming A Jaeger D Podar K Targeting the tumor microenvironment: focus on angiogenesis J Oncol 2012 281261 21876693 10.1155/2012/281261 PMC3163131
10 Samant RS Shevde LA Recent advances in anti-angiogenic therapy of cancer Oncotarget 2011 2 3 122 134 21399234 10.18632/oncotarget.234 PMC3260813
11 Jakob C Sterz J Zavrski I Heider U Kleeberg L Fleissner C Kaiser M Sezer O Angiogenesis in multiple myeloma Eur J Cancer 2006 42 11 1581 1590 16797965 10.1016/j.ejca.2006.02.017
12 Ribatti D Mangialardi G Vacca A Antiangiogenic therapeutic approaches in multiple myeloma Curr Cancer Drug Targets 2012 12 7 768 775 22780844 10.2174/156800912802429346
13 Hickey MM Simon MC Regulation of angiogenesis by hypoxia and hypoxia-inducible factors Curr Top Dev Biol 2006 76 217 257 17118268 10.1016/S0070-2153(06)76007-0
14 Martin SK Diamond P Williams SA To LB Peet DJ Fujii N Gronthos S Harris AL Zannettino AC Hypoxia-inducible factor-2 is a novel regulator of aberrant CXCL12 expression in multiple myeloma plasma cells Haematologica 95 5 776 784 20015878 10.3324/haematol.2009.015628 PMC2864384
15 Martin SK Diamond P Gronthos S Peet DJ Zannettino AC The emerging role of hypoxia, HIF-1 and HIF-2 in multiple myeloma Leukemia 25 10 1533 1542 21637285 10.1038/leu.2011.122
16 Zhang Y Li M Yao Q Chen C Recent advances in tumor hypoxia: tumor progression, molecular mechanisms, and therapeutic implications Med Sci Monit 2007 13 10 RA175 180 17901861
17 Storti P Bolzoni M Donofrio G Airoldi I Guasco D Toscani D Martella E Lazzaretti M Mancini C Agnelli L Patrene K Maiga S Franceschi V Colla S Anderson J Neri A Hypoxia-inducible factor (HIF)-1alpha suppression in myeloma cells blocks tumoral growth in vivo inhibiting angiogenesis and bone destruction Leukemia 27 8 1697 1706 23344526 10.1038/leu.2013.24
18 Hua Z Lv Q Ye W Wong CK Cai G Gu D Ji Y Zhao C Wang J Yang BB Zhang Y MiRNA-directed regulation of VEGF and other angiogenic factors under hypoxia PLoS One 2006 1 e116 17205120 10.1371/journal.pone.0000116 PMC1762435
19 Landskroner-Eiger S Moneke I Sessa WC miRNAs as modulators of angiogenesis Cold Spring Harb Perspect Med 3 2 a006643 23169571 10.1101/cshperspect.a006643 PMC3552340
20 Calin GA Croce CM MicroRNA signatures in human cancers Nat Rev Cancer 2006 6 11 857 866 17060945 10.1038/nrc1997
21 Lionetti M Agnelli L Mosca L Fabris S Andronache A Todoerti K Ronchetti D Deliliers GL Neri A Integrative high-resolution microarray analysis of human myeloma cell lines reveals deregulated miRNA expression associated with allelic imbalances and gene expression profiles Genes Chromosomes Cancer 2009 48 6 521 531 19306352 10.1002/gcc.20660
22 Lionetti M Biasiolo M Agnelli L Todoerti K Mosca L Fabris S Sales G Deliliers GL Bicciato S Lombardi L Bortoluzzi S Neri A Identification of microRNA expression patterns and definition of a microRNA/mRNA regulatory network in distinct molecular groups of multiple myeloma Blood 2009 114 25 e20 26 19846888 10.1182/blood-2009-08-237495
23 Lionetti M Agnelli L Lombardi L Tassone P Neri A MicroRNAs in the pathobiology of multiple myeloma Curr Cancer Drug Targets 2012 12 7 823 837 22671930 10.2174/156800912802429274
24 Benetatos L Vartholomatos G Deregulated microRNAs in multiple myeloma Cancer 2012 118 4 878 887 21837684 10.1002/cncr.26297
25 Chou J Shahi P Werb Z microRNA-mediated regulation of the tumor microenvironment Cell Cycle 2013 12 20 3262 3271 24036551 10.4161/cc.26087 PMC3885637
26 Nohata N Hanazawa T Enokida H Seki N microRNA-1/133a and microRNA-206/133b clusters: dysregulation and functional roles in human cancers Oncotarget 2012 3 1 9 21 22308266 10.18632/oncotarget.424 PMC3292888
27 Calin GA Croce CM MicroRNAs and chromosomal abnormalities in cancer cells Oncogene 2006 25 46 6202 6210 17028600 10.1038/sj.onc.1209910
28 Pichiorri F Suh SS Ladetto M Kuehl M Palumbo T Drandi D Taccioli C Zanesi N Alder H Hagan JP Munker R Volinia S Boccadoro M Garzon R Palumbo A Aqeilan RI MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis Proc Natl Acad Sci U S A 2008 105 35 12885 12890 18728182 10.1073/pnas.0806202105 PMC2529070
29 Tagliaferri P Rossi M Di Martino MT Amodio N Leone E Gulla A Neri A Tassone P Promises and challenges of MicroRNA-based treatment of multiple myeloma Curr Cancer Drug Targets 2012 12 7 838 846 22671926 10.2174/156800912802429355 PMC3504921
30 Di Martino MT Leone E Amodio N Foresta U Lionetti M Pitari MR Cantafio ME Gulla A Conforti F Morelli E Tomaino V Rossi M Negrini M Ferrarini M Caraglia M Shammas MA Synthetic miR-34a mimics as a novel therapeutic agent for multiple myeloma: in vitro and in vivo evidence Clin Cancer Res 2012 18 22 6260 6270 23035210 10.1158/1078-0432.CCR-12-1708 PMC4453928
31 Amodio N Leotta M Bellizzi D Di Martino MT D'Aquila P Lionetti M Fabiani F Leone E Gulla AM Passarino G Caraglia M Negrini M Neri A Giordano A Tagliaferri P Tassone P DNA-demethylating and anti-tumor activity of synthetic miR-29b mimics in multiple myeloma Oncotarget 2012 3 10 1246 1258 23100393 10.18632/oncotarget.675 PMC3717964
32 Amodio N Di Martino MT Foresta U Leone E Lionetti M Leotta M Gulla AM Pitari MR Conforti F Rossi M Agosti V Fulciniti M Misso G Morabito F Ferrarini M Neri A miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1 Cell Death Dis 2012 3 e436 23190608 10.1038/cddis.2012.175 PMC3542610
33 Rossi M Pitari MR Amodio N Di Martino MT Conforti F Leone E Botta C Paolino FM Del Giudice T Iuliano E Caraglia M Ferrarini M Giordano A Tagliaferri P Tassone P miR-29b negatively regulates human osteoclastic cell differentiation and function: implications for the treatment of multiple myeloma-related bone disease J Cell Physiol 2013 228 7 1506 1515 23254643 10.1002/jcp.24306
34 Di Martino MT Gulla A Cantafio ME Lionetti M Leone E Amodio N Guzzi PH Foresta U Conforti F Cannataro M Neri A Giordano A Tagliaferri P Tassone P In vitro and in vivo anti-tumor activity of miR-221/222 inhibitors in multiple myeloma Oncotarget 2013 4 2 242 255 23479461 10.18632/oncotarget.820 PMC3712570
35 Amodio N Di Martino MT Neri A Tagliaferri P Tassone P Non-coding RNA: a novel opportunity for the personalized treatment of multiple myeloma Expert Opin Biol Ther 2013 13 Suppl 1 S125 137 23692413 10.1517/14712598.2013.796356
36 Amodio N Bellizzi D Leotta M Raimondi L Biamonte L D'Aquila P Di Martino MT Calimeri T Rossi M Lionetti M Leone E Passarino G Neri A Giordano A Tagliaferri P Tassone P miR-29b induces SOCS-1 expression by promoter demethylation and negatively regulates migration of multiple myeloma and endothelial cells Cell Cycle 2013 12 23 3650 3662 24091729 10.4161/cc.26585 PMC3903716
37 Leone E Morelli E Di Martino MT Amodio N Foresta U Gulla A Rossi M Neri A Giordano A Munshi NC Anderson KC Tagliaferri P Tassone P Targeting miR-21 inhibits in vitro and in vivo multiple myeloma cell growth Clinical cancer research : an official journal of the American Association for Cancer Research 2013 19 8 2096 2106 23446999 10.1158/1078-0432.CCR-12-3325 PMC4147955
38 Kulshreshtha R Davuluri RV Calin GA Ivan M A microRNA component of the hypoxic response Cell Death Differ 2008 15 4 667 671 18219318 10.1038/sj.cdd.4402310
39 Kulshreshtha R Ferracin M Wojcik SE Garzon R Alder H Agosto-Perez FJ Davuluri R Liu CG Croce CM Negrini M Calin GA Ivan M A microRNA signature of hypoxia Mol Cell Biol 2007 27 5 1859 1867 17194750 10.1128/MCB.01395-06 PMC1820461
40 Chan SY Loscalzo J MicroRNA-210: a unique and pleiotropic hypoxamir Cell Cycle 2010 9 6 1072 1083 20237418 10.4161/cc.9.6.11006 PMC2912143
41 Shen Q Cicinnati VR Zhang X Iacob S Weber F Sotiropoulos GC Radtke A Lu M Paul A Gerken G Beckebaum S Role of microRNA-199a-5p and discoidin domain receptor 1 in human hepatocellular carcinoma invasion Mol Cancer 9 227 10.1186/1476-4598-9-227 PMC2939569 20799954
42 Gu S Chan WY Flexible and Versatile as a Chameleon-Sophisticated Functions of microRNA-199a Int J Mol Sci 13 7 8449 8466 22942713 10.3390/ijms13078449 PMC3430244
43 Song XW Li Q Lin L Wang XC Li DF Wang GK Ren AJ Wang YR Qin YW Yuan WJ Jing Q MicroRNAs are dynamically regulated in hypertrophic hearts, and miR-199a is essential for the maintenance of cell size in cardiomyocytes J Cell Physiol 225 2 437 443 20458739 10.1002/jcp.22217
44 Sayed D Abdellatif M AKT-ing via microRNA Cell Cycle 2010 9 16 3213 3217 20814244 10.4161/cc.9.16.12634 PMC3041162
45 Rane S He M Sayed D Yan L Vatner D Abdellatif M An antagonism between the AKT and beta-adrenergic signaling pathways mediated through their reciprocal effects on miR-199a-5p Cell Signal 22 7 1054 1062 20193759 10.1016/j.cellsig.2010.02.008 PMC2872486
46 Cheung HH Davis AJ Lee TL Pang AL Nagrani S Rennert OM Chan WY Methylation of an intronic region regulates miR-199a in testicular tumor malignancy Oncogene 30 31 3404 3415 21383689 10.1038/onc.2011.60 PMC3117973
47 Lujambio A Esteller M How epigenetics can explain human metastasis: a new role for microRNAs Cell Cycle 2009 8 3 377 382 19177007 10.4161/cc.8.3.7526
48 Di Raimondo F Azzaro MP Palumbo G Bagnato S Giustolisi G Floridia P Sortino G Giustolisi R Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral blood Haematologica 2000 85 8 800 805 10942925
49 Podar K Anderson KC The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications Blood 2005 105 4 1383 1395 15471951 10.1182/blood-2004-07-2909
50 Harris AL Hypoxia--a key regulatory factor in tumour growth Nat Rev Cancer 2002 2 1 38 47 11902584 10.1038/nrc704
51 Guimbellot JS Erickson SW Mehta T Wen H Page GP Sorscher EJ Hong JS Correlation of microRNA levels during hypoxia with predicted target mRNAs through genome-wide microarray analysis BMC Med Genomics 2009 2 15 19320992 10.1186/1755-8794-2-15 PMC2667434
52 Ghosh G Subramanian IV Adhikari N Zhang X Joshi HP Basi D Chandrashekhar YS Hall JL Roy S Zeng Y Ramakrishnan S Hypoxia-induced microRNA-424 expression in human endothelial cells regulates HIF-alpha isoforms and promotes angiogenesis J Clin Invest 120 11 4141 4154 20972335 10.1172/JCI42980 PMC2964978
53 Cascio S D'Andrea A Ferla R Surmacz E Gulotta E Amodeo V Bazan V Gebbia N Russo A miR-20b modulates VEGF expression by targeting HIF-1 alpha and STAT3 in MCF-7 breast cancer cells J Cell Physiol 224 1 242 249 20232316 10.1002/jcp.22126
54 Jia XQ Cheng HQ Qian X Bian CX Shi ZM Zhang JP Jiang BH Feng ZQ Lentivirus-mediated overexpression of microRNA-199a inhibits cell proliferation of human hepatocellular carcinoma Cell Biochem Biophys 62 1 237 244 21847633 10.1007/s12013-011-9263-8
55 Rane S He M Sayed D Vashistha H Malhotra A Sadoshima J Vatner DE Vatner SF Abdellatif M Downregulation of miR-199a derepresses hypoxia-inducible factor-1alpha and Sirtuin 1 and recapitulates hypoxia preconditioning in cardiac myocytes Circ Res 2009 104 7 879 886 19265035 10.1161/CIRCRESAHA.108.193102 PMC3332328
56 Gutierrez NC Sarasquete ME Misiewicz-Krzeminska I Delgado M De Las Rivas J Ticona FV Ferminan E Martin-Jimenez P Chillon C Risueno A Hernandez JM Garcia-Sanz R Gonzalez M San Miguel JF Deregulation of microRNA expression in the different genetic subtypes of multiple myeloma and correlation with gene expression profiling Leukemia 24 3 629 637 20054351 10.1038/leu.2009.274
57 Kriegl L Vieth M Kirchner T Menssen A Up-regulation of c-MYC and SIRT1 expression correlates with malignant transformation in the serrated route to colorectal cancer Oncotarget 2012 3 10 1182 1193 23045412 10.18632/oncotarget.628 PMC3717960
58 Colla S Morandi F Lazzaretti M Polistena P Svaldi M Coser P Bonomini S Hojden M Martella E Chisesi T Rizzoli V Giuliani N Do human myeloma cells directly produce basic FGF? Blood 2003 102 8 3071 3072 author reply 3072-3073 14527891 10.1182/blood-2003-06-1883
59 Colla S Tagliaferri S Morandi F Lunghi P Donofrio G Martorana D Mancini C Lazzaretti M Mazzera L Ravanetti L Bonomini S Ferrari L Miranda C Ladetto M Neri TM Neri A The new tumor-suppressor gene inhibitor of growth family member 4 (ING4) regulates the production of proangiogenic molecules by myeloma cells and suppresses hypoxia-inducible factor-1 alpha (HIF-1alpha) activity: involvement in myeloma-induced angiogenesis Blood 2007 110 13 4464 4475 17848618 10.1182/blood-2007-02-074617
60 Ria R Reale A De Luisi A Ferrucci A Moschetta M Vacca A Bone marrow angiogenesis and progression in multiple myeloma Am J Blood Res 1 1 76 89 22432068 PMC3301416
61 Vacca A Ribatti D Bone marrow angiogenesis in multiple myeloma Leukemia 2006 20 2 193 199 16357836 10.1038/sj.leu.2404067
62 Liu YL Yu JM Song XR Wang XW Xing LG Gao BB Regulation of the chemokine receptor CXCR4 and metastasis by hypoxia-inducible factor in non small cell lung cancer cell lines Cancer Biol Ther 2006 5 10 1320 1326 16929169 10.4161/cbt.5.10.3162
63 Sarvaiya PJ Guo D Ulasov I Gabikian P Lesniak MS Chemokines in tumor progression and metastasis Oncotarget 2013 4 12 2171 2185 24259307 10.18632/oncotarget.1426 PMC3926818
64 Vogel WF Aszodi A Alves F Pawson T Discoidin domain receptor 1 tyrosine kinase has an essential role in mammary gland development Mol Cell Biol 2001 21 8 2906 2917 11283268 10.1128/MCB.21.8.2906-2917.2001 PMC86919
65 Azab AK Hu J Quang P Azab F Pitsillides C Awwad R Thompson B Maiso P Sun JD Hart CP Roccaro AM Sacco A Ngo HT Lin CP Kung AL Carrasco RD Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like features Blood 119 24 5782 5794 22394600 10.1182/blood-2011-09-380410 PMC3382938
66 Guarino M Rubino B Ballabio G The role of epithelial-mesenchymal transition in cancer pathology Pathology 2007 39 3 305 318 17558857 10.1080/00313020701329914
67 Christiansen JJ Rajasekaran AK Reassessing epithelial to mesenchymal transition as a prerequisite for carcinoma invasion and metastasis Cancer Res 2006 66 17 8319 8326 16951136 10.1158/0008-5472.CAN-06-0410
68 Zhu GH Huang C Feng ZZ Lv XH Qiu ZJ Hypoxia-induced snail expression through transcriptional regulation by HIF-1alpha in pancreatic cancer cells Dig Dis Sci 58 12 3503 3515 23979441 10.1007/s10620-013-2841-4
69 Radisavljevic Z AKT as locus of cancer multidrug resistance and fragility J Cell Physiol 228 4 671 674 22886615 10.1002/jcp.24176
70 Markman B Dienstmann R Tabernero J Targeting the PI3K/Akt/mTOR pathway--beyond rapalogs Oncotarget 2010 1 7 530 543 21317449 10.18632/oncotarget.188 PMC3248125
71 Lee YB Bantounas I Lee DY Phylactou L Caldwell MA Uney JB Twist-1 regulates the miR-199a/214 cluster during development Nucleic Acids Res 2009 37 1 123 128 19029138 10.1093/nar/gkn920 PMC2615617
72 Misiewicz-Krzeminska I Sarasquete ME Quwaider D Krzeminski P Ticona FV Paino T Delgado M Aires A Ocio EM Garcia-Sanz R San Miguel JF Gutierrez NC Restoration of microRNA-214 expression reduces growth of myeloma cells through positive regulation of P53 and inhibition of DNA replication Haematologica 98 4 640 648 23100276 10.3324/haematol.2012.070011 PMC3659997
73 Mizuno S Chijiwa T Okamura T Akashi K Fukumaki Y Niho Y Sasaki H Expression of DNA methyltransferases DNMT1, 3A, and 3B in normal hematopoiesis and in acute and chronic myelogenous leukemia Blood 2001 97 5 1172 1179 11222358 10.1182/blood.v97.5.1172
74 Castiglia D Cestelli A Scaturro M Nastasi T Di Liegro I H1(0) and H3. 3B mRNA levels in developing rat brain Neurochem Res 1994 19 12 1531 1537 7877725 10.1007/BF00969002
75 Cestelli A Castiglia D Di Liegro C Di Liegro I Qualitative differences in nuclear proteins correlate with neuronal terminal differentiation Cell Mol Neurobiol 1992 12 1 33 43 1571953 10.1007/BF00711637 PMC11567481
76 Di Martino MT Leone E Amodio N Foresta U Lionetti M Pitari MR Cantafio ME Gulla A Conforti F Morelli E Tomaino V Rossi M Negrini M Ferrarini M Caraglia M Shammas MA Synthetic miR-34a mimics as a novel therapeutic agent for multiple myeloma: in vitro and in vivo evidence Clin Cancer Res 18 22 6260 6270 23035210 10.1158/1078-0432.CCR-12-1708 PMC4453928